AI English summary of an SEC filing — figures as filed
DaVita DVAThe company said operating cash flow for the 6 months ended June 30, 2024 decreased from the same period a year earlier. It cited decreased cash collections from the CHC Outage as the main factor, along with higher cash taxes paid and decreases in other working capital items.
Key points
AI summaryThe company said operating cash flow for the 6 months ended June 30, 2024 decreased from the same period a year earlier. It cited decreased cash collections from the CHC Outage as the main factor, along with higher cash taxes paid and decreases in other working capital items.
The company said it extended the maturity of part of its Term Loan B-1 (about $1,640 million) from August 2026 to May 2031, made a net draw of $260 million on its revolving line of credit, and repurchased 4,774,415 shares of its stock during the 6 months ended June 30, 2024.
DaVita said U.S. dialysis center closure costs were about $15.3 million in Q2 2024, which increased patient care costs by $6.5 million and general and administrative expenses by $8.7 million. It said closure costs in the prior quarter, Q1 2024, were about $14.6 million.
The company said that as of June 30, 2024, $1,240 million of its $1.5 billion revolving line of credit was available and $260 million was drawn. It said the CHC Outage continues to affect the submission of some claims, and that accounts receivable balances and DSO decreased during Q2.
Key figures
Quarter ended June 30, 2024
- Revenue
- $3.2B
- Operating income
- $506M
- Net income
- $223M
- EPS
- $2.50
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
CHC Outage and Operating Cash Flow
The company said operating cash flow for the 6 months ended June 30, 2024 decreased from the same period a year earlier. It cited decreased cash collections from the CHC Outage as the main factor, along with higher cash taxes paid and decreases in other working capital items.
Source · Based on the MD&A text of the filing
6-Month Borrowings, Repayments and Share Repurchases
The company said it extended the maturity of part of its Term Loan B-1 (about $1,640 million) from August 2026 to May 2031, made a net draw of $260 million on its revolving line of credit, and repurchased 4,774,415 shares of its stock during the 6 months ended June 30, 2024.
Source · Based on the MD&A text of the filing
U.S. Dialysis Center Closure Costs for Q2
DaVita said U.S. dialysis center closure costs were about $15.3 million in Q2 2024, which increased patient care costs by $6.5 million and general and administrative expenses by $8.7 million. It said closure costs in the prior quarter, Q1 2024, were about $14.6 million.
Source · Based on the MD&A text of the filing
Available Liquidity and CHC Impact
The company said that as of June 30, 2024, $1,240 million of its $1.5 billion revolving line of credit was available and $260 million was drawn. It said the CHC Outage continues to affect the submission of some claims, and that accounts receivable balances and DSO decreased during Q2.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…